Current therapy for hepatitis C: pegylated interferon and ribavirin
- 1 February 2003
- journal article
- review article
- Published by Elsevier in Clinics in Liver Disease
- Vol. 7 (1), 149-161
- https://doi.org/10.1016/s1089-3261(02)00077-6
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis CGastroenterology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis CGastroenterology, 2002
- Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapyExpert Opinion on Investigational Drugs, 2001
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis CHepatology, 2001
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Standardization of Hepatitis C Virus RNA QuantificationHepatology, 2000
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998